MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid t… Read more
MorphoSys AG (MPSYF) - Net Assets
Latest net assets as of March 2024: $-261.67 Million USD
Based on the latest financial reports, MorphoSys AG (MPSYF) has net assets worth $-261.67 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.83 Billion) and total liabilities ($2.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-261.67 Million |
| % of Total Assets | -14.29% |
| Annual Growth Rate | 4.21% |
| 5-Year Change | -87.57% |
| 10-Year Change | -85.94% |
| Growth Volatility | 37.68 |
MorphoSys AG - Net Assets Trend (2002–2023)
This chart illustrates how MorphoSys AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MorphoSys AG (2002–2023)
The table below shows the annual net assets of MorphoSys AG from 2002 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $49.05 Million | -68.84% |
| 2022-12-31 | $157.41 Million | -35.72% |
| 2021-12-31 | $244.88 Million | -60.59% |
| 2020-12-31 | $621.32 Million | +57.42% |
| 2019-12-31 | $394.70 Million | -19.18% |
| 2018-12-31 | $488.37 Million | +36.16% |
| 2017-12-31 | $358.67 Million | -13.67% |
| 2016-12-31 | $415.46 Million | +14.54% |
| 2015-12-31 | $362.74 Million | +3.99% |
| 2014-12-31 | $348.80 Million | -0.95% |
| 2013-12-31 | $352.15 Million | +74.32% |
| 2012-12-31 | $202.01 Million | +2.47% |
| 2011-12-31 | $197.14 Million | +6.03% |
| 2010-12-31 | $185.92 Million | +6.89% |
| 2009-12-31 | $173.93 Million | +7.38% |
| 2008-12-31 | $161.99 Million | +11.30% |
| 2007-12-31 | $145.54 Million | +45.46% |
| 2006-12-31 | $100.05 Million | +56.31% |
| 2005-12-31 | $64.01 Million | +62.55% |
| 2004-12-31 | $39.38 Million | +30.47% |
| 2003-12-31 | $30.18 Million | +46.41% |
| 2002-12-31 | $20.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MorphoSys AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 96324590400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.66 Million | 76.77% |
| Other Comprehensive Income | $88.44 Million | 180.30% |
| Other Components | $936.09 Million | 1908.48% |
| Total Equity | $49.05 Million | 100.00% |
MorphoSys AG Competitors by Market Cap
The table below lists competitors of MorphoSys AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PROLOGUE S.A.INH.B EO-30
F:69P
|
$16.92 Million |
|
Peninsula Land Limited
NSE:PENINLAND
|
$16.93 Million |
|
Uno&Company.Ltd
KQ:114630
|
$16.93 Million |
|
OpenSys M Bhd
KLSE:0040
|
$16.93 Million |
|
Lii Hen Industries Bhd
KLSE:7089
|
$16.92 Million |
|
VULCAN MINLS
F:VM3
|
$16.91 Million |
|
Winston Medical Supply Co., Ltd.
TWO:6817
|
$16.91 Million |
|
Circio Holding ASA
OL:CRNA
|
$16.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MorphoSys AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 157,409,549 to 49,049,239, a change of -108,360,310 (-68.8%).
- Net loss of 189,734,199 reduced equity.
- New share issuances of 102,695,820 increased equity.
- Other comprehensive income decreased equity by 26,891,150.
- Other factors increased equity by 5,569,219.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-189.73 Million | -386.82% |
| Share Issuances | $102.70 Million | +209.37% |
| Other Comprehensive Income | $-26.89 Million | -54.82% |
| Other Changes | $5.57 Million | +11.35% |
| Total Change | $- | -68.84% |
Book Value vs Market Value Analysis
This analysis compares MorphoSys AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 205.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 163.72x to 205.03x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.45 | $73.27 | x |
| 2003-12-31 | $0.58 | $73.27 | x |
| 2004-12-31 | $0.64 | $73.27 | x |
| 2005-12-31 | $0.92 | $73.27 | x |
| 2006-12-31 | $1.31 | $73.27 | x |
| 2007-12-31 | $1.68 | $73.27 | x |
| 2008-12-31 | $1.81 | $73.27 | x |
| 2009-12-31 | $1.93 | $73.27 | x |
| 2010-12-31 | $2.04 | $73.27 | x |
| 2011-12-31 | $2.13 | $73.27 | x |
| 2012-12-31 | $2.17 | $73.27 | x |
| 2013-12-31 | $3.56 | $73.27 | x |
| 2014-12-31 | $3.33 | $73.27 | x |
| 2015-12-31 | $3.46 | $73.27 | x |
| 2016-12-31 | $3.93 | $73.27 | x |
| 2017-12-31 | $3.10 | $73.27 | x |
| 2018-12-31 | $3.90 | $73.27 | x |
| 2019-12-31 | $3.12 | $73.27 | x |
| 2020-12-31 | $4.68 | $73.27 | x |
| 2021-12-31 | $1.83 | $73.27 | x |
| 2022-12-31 | $1.15 | $73.27 | x |
| 2023-12-31 | $0.36 | $73.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MorphoSys AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -386.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79.63%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 41.31x
- Recent ROE (-386.82%) is below the historical average (-37.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -118.25% | -145.47% | 0.40x | 2.06x | $-26.44 Million |
| 2003 | -13.74% | -27.10% | 0.33x | 1.52x | $-7.17 Million |
| 2004 | 0.72% | 1.28% | 0.39x | 1.42x | $-3.66 Million |
| 2005 | 7.31% | 58.61% | 0.10x | 1.25x | $-1.72 Million |
| 2006 | 6.02% | 11.37% | 0.41x | 1.28x | $-3.98 Million |
| 2007 | 7.88% | 18.52% | 0.34x | 1.27x | $-3.08 Million |
| 2008 | 8.12% | 18.36% | 0.35x | 1.25x | $-3.05 Million |
| 2009 | 5.15% | 11.06% | 0.39x | 1.18x | $-8.43 Million |
| 2010 | 4.95% | 10.57% | 0.41x | 1.14x | $-9.40 Million |
| 2011 | 4.17% | 8.15% | 0.44x | 1.16x | $-11.50 Million |
| 2012 | 0.96% | 3.74% | 0.23x | 1.11x | $-18.26 Million |
| 2013 | 3.78% | 17.09% | 0.17x | 1.27x | $-21.89 Million |
| 2014 | -0.86% | -4.71% | 0.15x | 1.22x | $-37.89 Million |
| 2015 | 4.11% | 14.03% | 0.27x | 1.10x | $-21.37 Million |
| 2016 | -14.53% | -121.39% | 0.11x | 1.12x | $-101.93 Million |
| 2017 | -19.47% | -104.54% | 0.16x | 1.16x | $-105.69 Million |
| 2018 | -11.50% | -73.48% | 0.14x | 1.10x | $-105.01 Million |
| 2019 | -26.10% | -143.56% | 0.14x | 1.26x | $-142.48 Million |
| 2020 | 15.76% | 29.87% | 0.20x | 2.67x | $35.76 Million |
| 2021 | -210.11% | -286.47% | 0.07x | 10.44x | $-538.99 Million |
| 2022 | -95.96% | -54.29% | 0.12x | 15.23x | $-166.80 Million |
| 2023 | -386.82% | -79.63% | 0.12x | 41.31x | $-194.64 Million |
Industry Comparison
This section compares MorphoSys AG's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MorphoSys AG (MPSYF) | $-261.67 Million | -118.25% | N/A | $16.92 Million |
| Abcam plc (ABCZF) | $15.07 Million | 22.73% | 0.21x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $7.09 Million | -104.63% | 5.72x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.71 Million |
| Adamas Trust, Inc. (ADAMG) | $1.41 Billion | -4.40% | 5.53x | $2.07 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $13.74 Million | 0.00% | 2.67x | $9.38 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $51.99 Million | -0.21% | 3.57x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $1.03 Million | -345.23% | 6.23x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $2.41 Billion | -5.83% | 0.11x | $119.23K |
| Alvotech Warrant (ALVOW) | $-412.77 Million | 0.00% | 0.00x | $35.01 Million |